Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azole-echinocandin combination therapy for invasive aspergillosis (IA-DUET)
2020-000627-40Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Aug 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in invasive aspergillosis (IA) and aspergillosis comparing Triazole + anidulafungin with Triazole standard of care (2 arms). Primary endpoint: Overall survival at 6 weeks (MITT population). Started Aug 2020; status: active.
02
Drugs
anidulafungin
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on 2020-000627-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000627-40.